- Trials with a EudraCT protocol (29)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
29 result(s) found for: Optic neuropathy.
Displaying page 1 of 2.
EudraCT Number: 2011-001034-42 | Sponsor Protocol Number: SNT-II-003-OFU | Start Date*: 2011-08-25 | |||||||||||
Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited | |||||||||||||
Full Title: A single visit, observational, follow-up study of Patients with Leber’s Hereditary Optic Neuropathy following participation in SNT-II-003 trial | |||||||||||||
Medical condition: Leber’s Hereditary Optic Neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016982-26 | Sponsor Protocol Number: ST200-ODU-09-01 | Start Date*: 2010-11-04 | |||||||||||
Sponsor Name:SIGMA-TAU | |||||||||||||
Full Title: Neuronal conduction along the visual patways after oral treatment with Acetyl-L-carnitine in patients with Leber’s Hereditary Optic Neuropathy | |||||||||||||
Medical condition: Leber’s Hereditary Optic Neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005264-60 | Sponsor Protocol Number: CHF6467-OPG | Start Date*: 2021-11-26 | |||||||||||
Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE | |||||||||||||
Full Title: Safety and Efficacy of multiple doses of the PAINLESS Nerve Growth Factor CHF6467 in subjects with Optic Pathway Glioma (OPG). A randomized clinical trial (RCT) | |||||||||||||
Medical condition: Optic pathway glioma - optic neuropathy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001405-90 | Sponsor Protocol Number: GS-LHON/CLIN/01 | Start Date*: 2013-12-26 | |||||||||||
Sponsor Name:GENSIGHT-BIOLOGICS | |||||||||||||
Full Title: A phase I/IIa, non randomized, escalating dose, open-label study to evaluate safety and efficacy of GS010 (rAAV2/2-ND4) in patients suffering from Leber Hereditary Optic Neuropathy due to mutations... | |||||||||||||
Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002679-42 | Sponsor Protocol Number: SNT-II-003 | Start Date*: 2006-11-22 |
Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited | ||
Full Title: A double blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of idebenone in the treatment of patients with Leber's Hereditary Optic Neuropathy | ||
Medical condition: Leber's Hereditary Optic Neuropathy | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-002303-14 | Sponsor Protocol Number: A5951110 | Start Date*: 2008-12-17 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY10017, USA | |||||||||||||
Full Title: PROSPECTIVE STUDY OF OPHTHALMOLOGIC FUNCTION IN PATIENTS RECEIVING LINEZOLID FOR TWO MONTHS OR GREATER | |||||||||||||
Medical condition: This study is designed to understand the effects of linezolid on the optic nerve by observing and following patients who have been treated with linezolid for two months or longer for the developmen... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002187-40 | Sponsor Protocol Number: GS-LHON-CLIN-05 | Start Date*: 2018-03-15 |
Sponsor Name:GENSIGHT BIOLOGICS | ||
Full Title: Efficacy and Safety of Bilateral Intravitreal Injection of GS010: A Randomized, Double-Masked, Placebo-Controlled Trial in Subjects Affected with G11778A ND4 Leber Hereditary Optic Neuropathy for U... | ||
Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) NL (Ongoing) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002153-11 | Sponsor Protocol Number: GS-LHON-CLIN-06 | Start Date*: 2018-02-12 | |||||||||||
Sponsor Name:GENSIGHT BIOLOGICS | |||||||||||||
Full Title: Long-term Follow-up of ND4 LHON Subjects Treated With GS010 Ocular Gene Therapy in the RESCUE or REVERSE Phase III Clinical Trials | |||||||||||||
Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023586-22 | Sponsor Protocol Number: BAY38-9456/12912 | Start Date*: 2012-06-08 |
Sponsor Name:Bayer AG | ||
Full Title: Prospective Case Crossover Study to Assess Whether PDE5 Inhibitor Exposure in Men Increases the Risk for the Development of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) | ||
Medical condition: Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-003029-40 | Sponsor Protocol Number: IOBA-01-2016 | Start Date*: 2017-02-14 |
Sponsor Name:IOBA - University of Valladolid | ||
Full Title: Phase II safety assessment of intravitreal injection of mesenchymal stem cells for acute non arteritic anterior ischemic optic neuropathy (NAION) | ||
Medical condition: Non arteritic anterior ischemic optic neuropathy (NAION) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004405-16 | Sponsor Protocol Number: SNT-IV-005 | Start Date*: 2016-03-16 | |||||||||||
Sponsor Name:Santhera Pharmaceuticals (Switzerland) Limited | |||||||||||||
Full Title: External Natural History Controlled, open-Label Intervention Study to Assess the Efficacy and Safety of Long-Term Treatment with Raxone® in Leber’s Hereditary Optic Neuropathy (LHON) | |||||||||||||
Medical condition: Leber’s Hereditary Optic Neuropathy / LHON is a maternally inherited loss of vision due to atrophy of the optic nerve. It typically presents in young adults, mostly men, as painless acute or subacu... | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) BE (Completed) PT (Completed) ES (Completed) BG (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002112-27 | Sponsor Protocol Number: MD1003CT2013-01MS-ON | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:MEDDAY SAS | ||||||||||||||||||
Full Title: Effect of MD1003 in chronic visual loss related to optic neuritis in multiple sclerosis: a pivotal randomized double masked placebo controlled study | ||||||||||||||||||
Medical condition: chronic visual loss related to optic neuritis in multiple sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001265-11 | Sponsor Protocol Number: GS-LHON-CLIN-03A | Start Date*: 2016-01-21 |
Sponsor Name:GENSIGHT-BIOLOGICS | ||
Full Title: A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for 6 Months or Less by... | ||
Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-000848-14 | Sponsor Protocol Number: 38RC12.228 | Start Date*: 2014-07-23 |
Sponsor Name:Centre Hospitalier Universitaire de Grenoble | ||
Full Title: Endothelin and Ischemic optic Neuropathy study group | ||
Medical condition: Endothelin and Ischemic Optic Neuropathy study group | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-003079-31 | Sponsor Protocol Number: QRK207 | Start Date*: 2016-10-20 | |||||||||||
Sponsor Name:Quark Pharmaceuticals Inc. | |||||||||||||
Full Title: A PHASE 2/3, RANDOMIZED, DOUBLE-MASKED, SHAMCONTROLLED TRIAL OF QPI-1007 DELIVERED BY SINGLE OR MULTI-DOSE INTRAVITREAL INJECTION(S) TO SUBJECTS WITH ACUTE NONARTERITIC ANTERIOR ISCHEMIC OPTIC NEU... | |||||||||||||
Medical condition: NAION typically presents as an abrupt, painless monocular vision loss. Visual loss varies widely, ranging from visual field loss only to complete blindness. The neuronal degeneration process in N... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001145-40 | Sponsor Protocol Number: P17-03 | Start Date*: 2019-11-06 | ||||||||||||||||
Sponsor Name:Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts | ||||||||||||||||||
Full Title: French prospective open label phase II randomized non-comparative study of SC tocilizumab associated with IV pulse steroid versus IV pulse steroid alone for the treatment of acute anterior ischemic... | ||||||||||||||||||
Medical condition: Giant cell arteritis, acute anterior ischemic optic neuropathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004982-28 | Sponsor Protocol Number: FFIS/PG/2017/03 | Start Date*: 2018-05-23 |
Sponsor Name:Fundación para la Formación e Investigación Sanitarias de la Región de Murcia | ||
Full Title: Phase IIb prospective, unicentric, randomized, parallel, double-blind, placebo-controlled clinical trial to evaluate the intravenous infusion of prostaglandins as therapy in patients with non-arter... | ||
Medical condition: Non-arteritic anterior ischemic optic neuropathy (NOIANA). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001266-26 | Sponsor Protocol Number: GS-LHON-CLIN-03B | Start Date*: 2016-01-21 |
Sponsor Name:GENSIGHT-BIOLOGICS | ||
Full Title: A Randomized, Double-Masked, Sham-Controlled, Pivotal Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection of GS010 (rAAV2/2-ND4) in Subjects Affected for more than 6 months a... | ||
Medical condition: Leber Hereditary Optic Neuropathy due to mutations in the mitochondrial NADH Dehydrogenase 4 gene | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) GB (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001196-20 | Sponsor Protocol Number: H2013 | Start Date*: 2013-09-24 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO MILANO | |||||||||||||
Full Title: PROSPECTIVE STUDY ON THE EFFECTIVENESS OF TWO DIFFERENT DOSES OF INTRAVENOUS METHYLPREDNISOLONE IN THE TREATMENT OF ACUTE DYSTHYROID OPTIC NEUROPATHY | |||||||||||||
Medical condition: GRAVES' ORBITOPATHY | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002511-34 | Sponsor Protocol Number: V1.0.14062017 | Start Date*: 2018-09-26 |
Sponsor Name:Academisch Medisch Centrum | ||
Full Title: Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in CIDP (OPTIC trial) | ||
Medical condition: Chronic inflammatory demyelinating polyneuropathy (CIDP) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
